A new clinical trial listing for tirzepatide (LY3298176) was recorded on September 25, 2026. The study, titled "Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity" and known as ADVANCE-SURMOUNT-KIDS, is registered under identifier NCT07817875.
The trial is designated Phase 3 and is currently listed with a status of not yet recruiting. According to the registration, the study is designed to compare tirzepatide given once weekly against placebo in pediatric participants between 6 and less than 12 years of age who have obesity. The listing indicates the study will examine efficacy, safety, and pharmacokinetics as part of its scope, though no results or outcome data have been posted at this stage.
Tirzepatide is currently an approved compound, and this registration reflects an expansion of clinical investigation into a younger pediatric population. As the trial has not yet begun recruiting participants, no timeline for enrollment, completion, or data availability has been specified in the registration record. Further updates would be expected once recruitment status changes.
Readers can consult the compound overview for additional background on tirzepatide.